In 2012, the company posted a net profit of RON27.1 million.
Antibiotice’s sales rose 4.4% to RON317.4 million, from RON304.1 million in 2012, contributing to a 23% increase of the operating profit. The company, one of the largest medicine exporters in Romania, posted an operating result of RON51.5 million, from RON41.8 million in the previous year, according to its preliminary financial report for 2013.
The growth was mainly fueled by exports, according to previous statements of company representatives. Last year, Antibiotice’s external deliveries amounted to almost $27 million, about 30% of its sales.
Antibiotice is seeking to strengthen its exports amid the increasingly more challenging domestic market. The value of export revenue should double by 2020, company general manager Ioan Nani said back in January.
On the Romanian market, Antibiotice ranks 11th, with a share of 2.5%, according to market researcher Cegedim.
With about 53% of its shares in the hands of the Health Ministry, Antibiotice has a market value of RON412.9 million. Its shares closed up 0.16% at RON0.615 in Bucharest Monday. (EUR1=RON4.4754)